Based on ODYSSEY Outcomes and FOURIER, what are the findings and/or biologic risk features—Lp(a), for example—in patients managed in an interventional cardiology setting that would make you advocate for the use of PCSK9 inhibitors?

Name: Based on ODYSSEY Outcomes and FOURIER, what are the findings and/or biologic risk features—Lp(a), for example—in patients managed in an interventional cardiology setting that would make you advocate for the use of PCSK9 inhibitors?
Uploaded: 2019-03-05T00:00:00+00:00

CLICK HERE FOR CME CREDIT

Created by

Presenter

Phillipe Steg, MD

Professor of Cardiology
Université Paris – Diderot, Sorbonne-Paris Cité
Professor, National Heart and Lung Institute
Imperial College, London, UK
Director, Coronary Care Unit
Hôpital Bichat
Paris, France